Ocular Therapeutix Inc (OCUL) has disclosed a new risk, in the Taxation & Government Incentives category.
Ocular Therapeutix Inc. faces significant business risks due to potential disruptions in the operations of government agencies like the FDA and the SEC. These disruptions, stemming from inadequate funding, government shutdowns, or public health emergencies, can delay the review and approval of new product candidates. Such delays are exacerbated by fluctuating review times and the unpredictable political process governing agency funding. Consequently, the company’s ability to commercialize new products and access public markets might be adversely affected, posing a material risk to its business operations.
The average OCUL stock price target is $18.17, implying 206.67% upside potential.
To learn more about Ocular Therapeutix Inc’s risk factors, click here.